ELISA News and Research

RSS

Males may have higher but more transient SARS-CoV-2 immunity than females post-infection

Adding another piece to the puzzle that is coronavirus disease 2019 (COVID-19) serology, a new study published on the preprint server medRxiv* in November 2020 suggests that males have stronger but more transient anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protective immunity than females.

17 Nov 2020

Promising SARS-CoV-2 N epitope for more accurate diagnostic and surveillance antibody testing

A new study published on the preprint server bioRxiv in November 2020 describes the virus's N protein as a promising epitope for serology.

12 Nov 2020

Research tracks humoral immunity response over eight months post COVID-19 infection

Researchers from Chongqing Medical University have tried to answer one of the burning questions regarding the longevity of immune response to coronavirus disease 2019 (COVID-19): How long does immunity last after infection? Their study looked at the lasting effects and continued immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) over eight months after recovery from the infection.

11 Nov 2020

Critically ill COVID-19 patients experience novel platelet-activating immune complexes, study finds

Canadian researchers from McMaster University, Ontario, have pinpointed platelet activating immune complexes in coagulation disorders associated with coronavirus disease 2019 (COVID-19), the condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Nov 2020

Lateral flow test enables faster, accurate diagnosis of periprosthetic joint infection

The recently FDA-authorized alpha-defensin lateral flow test is a highly accurate, ten-minute test for diagnosis of periprosthetic joint infection (PJI) - a serious and costly complication of total joint replacement, reports a study in The Journal of Bone & Joint Surgery.

9 Nov 2020

Study suggests herd immunity to COVID-19 in New York City is low

Researchers in the United States have estimated that the proportion of people in New York City who developed antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first wave of the coronavirus disease 2019 (COVID-19) pandemic is around one in eight.

9 Nov 2020

Study shows SARS-CoV-2 infection four times more likely through household transmission than community

A group of researchers from across the United States working in collaboration with their Swiss counterparts have conducted an extensive population-based serological survey to understand the transmission dynamics of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) – the novel agent that causes coronavirus disease 2019 (COVID-19).

8 Nov 2020

Cats shed SARS-CoV-2 RNA for a shorter duration compared to humans, study finds

Since the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease 2019 (COVID-19), there have been numerous reports of pets becoming infected. Both dogs and cats have been observed to exhibit symptoms of infection.

8 Nov 2020

Pre-existing anti-IFN autoantibodies may worsen COVID-19 in lupus patients

“Our observations suggest that the presence of these autoantibodies may predispose SLE patients to infection with SARS-CoV-2 with a more severe presentation and represent an additional risk factor in this patient population,” write Sarthak Gupta and colleagues from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, Maryland.

5 Nov 2020

Chikungunya can infect central nervous system and impair cognitive, motor functions

A study conducted by an international team of researchers with FAPESP's support shows that infection by chikungunya virus can produce even more severe manifestations than the typical symptoms of the disease, such as acute fever, headache, rash, and intense joint and muscle pain.

4 Nov 2020

Evidence of robust and persistent antibodies against SARS-CoV-2

A team of researchers from the Icahn School of Medicine at Mount Sinai, New York, have worked in collaboration to try and answer one of the most baffling questions surrounding the coronavirus disease 19 (COVID-19) pandemic: do antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) last after a primary infection?

3 Nov 2020

They work in several nursing homes to eke out a living, possibly spreading the virus

To make ends meet, Martha Tapia works 64 hours a week at two Orange County, California, nursing homes. She is one of thousands of certified nursing assistants who perform the intimate and physical work of bathing, dressing and feeding the nation’s fragile elderly.

2 Nov 2020

MD65 IgG-YTE shows powerful post-exposure neutralization of SARS-CoV-2

A recent study published in the preprint server bioRxiv in October 2020 describes a reliable animal model to demonstrate the powerful capacity of human neutralizing mAbs directed against SARS-CoV-2 to prevent viral binding the host cell receptor and thus block infection. This indicates the lifesaving value of mAbs in severe COVID-19.

29 Oct 2020

Majority of people infected with mild-to-moderate COVID 19 mount robust antibody response

The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science.

29 Oct 2020

Scientists compare ACE2 interaction with SARS-CoV-2 across species

Like other pathogenic coronaviruses, SARS-CoV-2 crossed the species barrier to cause human disease. This fact motivated the current study, published on the preprint server bioRxiv* in October 2020, which explores the way coronaviruses engage their host cell receptors in a range of animals.

28 Oct 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

ACROBiosystems and the Fight Against COVID-19

In this interview, Dr. Yinang Jiang discusses ACROBiosystems and their efforts in the fight against COVID-19 and the search for a vaccine

From ACROBiosystems 23 Oct 2020

New method can detect high levels of COVID-19 antibodies

A more efficient and much faster method to assess high levels of neutralizing antibodies to COVID-19 could point the way to better understanding and treatment of the disease, according to new published findings by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) and the University of Michigan (U-M).

23 Oct 2020

Seropositivity to SARS-CoV-2 among asymptomatic blood donors in New York

New York was the hardest-hit U.S. state during the peak of the outbreak in the country. Now, a team of researchers from the New York Blood Center and Serimmune, an immune intelligence company, aimed to determine the prevalence of seropositive people for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, among healthy blood donors.